A Population-Based Analysis of Mediastinal Staging for Non-Small Cell Lung Cancer
A Population-Based Analysis of Mediastinal Staging for Non-Small Cell Lung Cancer
批准号:
7329894
负责人:
Farhood Farjah
金额:
$5.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-01 至 2008-06-24
关键词:
AdoptionAffectCancer EtiologyCancer PatientCaringCessation of lifeCharacteristicsClinical TrialsCommunitiesCountryDiagnosisDiagnosticDiseaseDisease regressionExcisionFrequenciesGeographic LocationsGoalsInvasiveLinkLogistic RegressionsLungMalignant NeoplasmsMediastinalMediastinal lymph node groupMediastinoscopyMediastinumMedicareMethodsModalityNon-Small-Cell Lung CarcinomaOutcomePatientsPopulationPositron-Emission TomographyPractice GuidelinesRecommendationReportingRiskRisk EstimateStagingTechnologyTherapy Clinical TrialsTimeUncertaintyVariantWorkX-Ray Computed Tomographybasecohortdiagnostic accuracyneoplasm registryprospectivetrend
中文摘要
描述(申请人提供):非小细胞肺癌(NSCLC)是该国第二常见的癌症,也是与癌症相关的死亡的主要原因。一般来说,那些没有肿瘤扩散到纵隔淋巴结的人会接受根治性的肺切除,而那些有纵隔淋巴结疾病的人会接受姑息化疗。采用非侵入性和/或侵入性诊断方法对纵隔进行分期。由于任何单一诊断方法的诊断准确性有限,最佳纵隔分期可能需要使用不止一种诊断方法。然而,基于证据的分期方法尚未建立,实践指南也没有提供一致的建议。整个社区如何利用各种分期模式的组合尚不清楚。由于新的分期技术、科学的不确定性和护理上的差异,分期方法可能会随着时间、地理位置和社会人口学因素而发生变化。分期模式的组合使用的变化从未被描述过。分期可能通过适当和不适当的治疗分配来影响结果。纵隔淋巴结不足的患者不必要地面临肺切除的风险和后果,而那些纵隔淋巴结高估的患者则被拒绝接受潜在的根治疗法。分期和存活率之间的关系从未被报道过。该项目的总体目标是利用与医疗保险索赔相关的大型癌症登记来描述1998至2002年间确诊的非小细胞肺癌患者队列中的纵隔分期。我们的目标是1)描述与使用不同纵隔分期方式组合相关的时间趋势、区域差异和患者因素;以及2)探索纵隔分期方式不同组合与生存率之间的关系。泊松回归将被用来评估正电子发射断层扫描(PET)随时间的使用频率。Logistic回归将用于评估地理区域和/或患者特征是否能预测计算机断层扫描、正电子发射计算机断层扫描和纵隔镜的联合应用。最后,将使用COX多变量回归对广泛纵隔分期与生存率之间的关系进行探索性分析。这项工作的发现将有助于证明前瞻性临床试验更适合于为不同的分期策略提供风险调整后的生存率的无偏见估计。从这一系列工作中出现的证据也对质量改进倡议和将标准化分期纳入治疗的临床试验具有意义。
英文摘要
DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is the second most common cancer and the leading cause of cancer- related deaths in this country. In general, those without spread of cancer to mediastinal lymph nodes undergo curative lung resection, and those with mediastinal lymph node disease undergo palliative chemoradiation therapy. Non-invasive and/or invasive diagnostic modalities are used to stage the mediastinum. Because of the limited diagnostic accuracy of any single modality, optimal mediastinal staging likely requires the use of more than one diagnostic modality. However, an evidence-based approach to staging has yet to be established and practice guidelines do not provide consistent recommendations. How the community at large utilizes combinations of staging modalities is unknown. Variation in the approach to staging may occur over time, geographic location, and sociodemographic factors as a result of new staging technology, scientific uncertainty, and disparities in care, respectively. Variation in the use of combinations of staging modalities has never been described. Staging likely affects outcomes through the appropriate and inappropriate allocation of treatment. Patients with understaged mediastinal lymph nodes are unnecessarily exposed to the risks and consequences of a lung resection, whereas those with overstaged mediastinal lymph nodes are denied a potentially curative therapy. An association between staging and survival has never been reported. The overall goal of this project is to characterize mediastinal staging in a cohort of patients diagnosed with NSCLC between 1998 and 2002 using a large cancer registry linked to Medicare claims. We aim to 1) describe temporal trends, regional variation, and patient factors associated with the use of different combinations of mediastinal staging modalities; and 2) explore the association between different combinations of mediastinal staging modalities and survival. Poisson regression will be used to evaluate the frequency of use of positron emission tomography (PET) over time. Logistic regression will be used to evaluate whether geographic area and/or patient characteristics predict the use of computed tomography, PET, and mediastinoscopy in combination. Finally, Cox multivariate regression will be used to perform an exploratory analysis of an association between the use of extensive mediastinal staging and survival. Findings from this work will help justify prospective clinical trials better suited to provide unbiased estimates of risk-adjusted survival for differing staging strategies. The body of evidence emerging from this line of work also has implications for quality improvement initiatives and incorporating standardized staging into clinical trials of therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction
-
批准号:10677741
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2022
-
负责人:Farhood Farjah
-
依托单位:
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction
-
批准号:10426535
-
项目类别:
-
资助金额:$44.99万
-
财政年份:2022
-
负责人:Farhood Farjah
-
依托单位:
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging
-
批准号:10551866
-
项目类别:
-
资助金额:$60.06万
-
财政年份:2022
-
负责人:Farhood Farjah
-
依托单位:
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging
-
批准号:10365806
-
项目类别:
-
资助金额:$66.57万
-
财政年份:2022
-
负责人:Farhood Farjah
-
依托单位:
海外基金